Literature DB >> 31465959

Dynamic factors affecting HPV-attributable fraction for head and neck cancers.

Jitesh B Shewale1, Maura L Gillison2.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is attributable to carcinogen and oncogenic virus exposure and rates are driven by the prevalence, intensity, and duration of exposures. Recent dramatic shifts in human behavior have resulted in substantial heterogeneity in HNSCC incidence trends over calendar time. For example, changes in sexual behavior during the 1900s likely increased exposure to oral human papillomavirus (HPV) infection and, consequently, rates of HPV-positive HNSCC. Shifting rate-ratios for HPV-positive versus negative HNSCC determine the HPV attributable fraction (AF), best measured by direct tumor testing for HPV DNA and RNA. Potential high efficacy of HPV vaccines against oral HPV infections will affect future incidence trends, depending on calendar time of introduction, male and female coverage, and herd protection. Accurate estimates of HPV AF for all cancers, including HNSCC, may inform HPV immunization policy and surveillance of effectiveness.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Year:  2019        PMID: 31465959     DOI: 10.1016/j.coviro.2019.07.008

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  5 in total

Review 1.  Is early-onset cancer an emerging global epidemic? Current evidence and future implications.

Authors:  Tomotaka Ugai; Naoko Sasamoto; Hwa-Young Lee; Mariko Ando; Mingyang Song; Rulla M Tamimi; Ichiro Kawachi; Peter T Campbell; Edward L Giovannucci; Elisabete Weiderpass; Timothy R Rebbeck; Shuji Ogino
Journal:  Nat Rev Clin Oncol       Date:  2022-09-06       Impact factor: 65.011

Review 2.  Subversion of Host Innate Immunity by Human Papillomavirus Oncoproteins.

Authors:  Irene Lo Cigno; Federica Calati; Silvia Albertini; Marisa Gariglio
Journal:  Pathogens       Date:  2020-04-17

3.  Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model.

Authors:  Sonia Domingos-Pereira; Vincent Roh; Agnès Hiou-Feige; Gabriele Galliverti; Christian Simon; Genrich V Tolstonog; Denise Nardelli-Haefliger
Journal:  Oncoimmunology       Date:  2021-04-13       Impact factor: 8.110

4.  Active immunization combined with cisplatin confers enhanced therapeutic protection and prevents relapses of HPV-induced tumors at different anatomical sites.

Authors:  Bruna Felício Milazzotto Maldonado Porchia; Luana Raposo de Melo Moraes Aps; Ana Carolina Ramos Moreno; Jamile Ramos da Silva; Mariângela de Oliveira Silva; Natiely Silva Sales; Rubens Prince Dos Santos Alves; Clarissa Ribeiro Reily Rocha; Matheus Molina Silva; Karine Bitencourt Rodrigues; Tácita Borges Barros; Roberta Liberato Pagni; Patrícia da Cruz Souza; Mariana de Oliveira Diniz; Luís Carlos de Souza Ferreira
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

5.  Human Papillomavirus Oral- and Sero- Positivity in Fanconi Anemia.

Authors:  Sharon L Sauter; Xue Zhang; Lindsey Romick-Rosendale; Susanne I Wells; Kasiani C Myers; Marion G Brusadelli; Charles B Poff; Darron R Brown; Gitika Panicker; Elizabeth R Unger; Parinda A Mehta; Jack Bleesing; Stella M Davies; Melinda Butsch Kovacic
Journal:  Cancers (Basel)       Date:  2021-03-18       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.